Related Experiment Videos
Cyclosporin pharmacokinetics in paediatric transplant recipients
G F Cooney1, K Habucky, K Hoppu
1Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA. cooneygf@vm.temple.edu
Insights
Pediatric organ transplant patients require higher cyclosporin doses due to age-related bioavailability and metabolic differences. Younger children may benefit from three-times-daily dosing for optimal antirejection therapy.
Area of Science:
- Pharmacology
- Transplantation
- Pediatrics
Background:
- Cyclosporin is vital for preventing organ rejection in pediatric transplant recipients.
- Limited pharmacokinetic data exists for pediatric cyclosporin use compared to adults.
- Variability in study designs complicates direct comparisons.
Purpose of the Study:
- To analyze cyclosporin pharmacokinetics in pediatric organ transplant recipients.
- To compare pediatric pharmacokinetic data with adult transplant recipients.
- To inform dosing and monitoring guidelines for pediatric cyclosporin therapy.
Main Methods:
- Review of 14 publications on pediatric cyclosporin pharmacokinetics.
- Comparative analysis of pharmacokinetic data across different pediatric age groups and transplant types.
- Evaluation of factors influencing cyclosporin bioavailability and clearance in children.
Main Results:
- Cyclosporin bioavailability is highly variable in children, correlating with age, especially in liver transplant patients.
- Systemic clearance of cyclosporin is higher in pediatric patients than in adults.
- Pediatric patients generally need higher cyclosporin doses to reach therapeutic concentrations.
Conclusions:
- Age-related differences in bioavailability and potentially increased metabolic clearance necessitate higher cyclosporin doses in children.
- Younger pediatric patients (<8 years) may achieve better outcomes with a three-times-daily dosing regimen.
- Optimized dosing and monitoring are crucial for effective long-term cyclosporin management in pediatric transplant recipients.
Abstract:
Cyclosporin is an essential component of the antirejection drug protocol used in the long term management of paediatric organ transplant recipients. This article looks at the pharmacokinetics of cyclosporin in paediatric kidney, heart, liver and bone marrow transplant recipients and critically evaluates its relationship to pharmacokinetic data in adult transplant recipients. There are limited data on the pharmacokinetics of cyclosporin in paediatric transplant recipients (14 publications provide the database) as compared with the adult transplant population. Study design, analytical methodology and age ranges of the individuals differ between studies, making comparative interpretation of pharmacokinetic data difficult. However, significant trends are noteworthy and these may influence dose administration guidelines and therapeutic monitoring standards for cyclosporin in the paediatric organ transplant recipient. The bioavailability of the oral formulations of cyclosporin is highly variable as with the adult population, but there appears to be a correlation between cyclosporin bioavailability and age with both the traditional oral formulation (Sandimmun) and the new microemulsion formulation (Neoral) in young liver transplant patients. Bowel length, presystemic metabolism in the gut wall, type of transplant and time since transplant are contributing factors in the variation of bioavailability patterns in paediatric transplant patients. The volume of distribution of cyclosporin does not appear to differ between paediatric and adult transplant recipients, but systemic clearance is comparatively higher in the paediatric population. In general, paediatric patients require higher doses of cyclosporin to achieve target blood concentrations of the drug which are equivalent to the values used in the adult population. Younger patients (less than 8 years of age) may be managed more effectively with a 3 times daily administration schedule rather than the twice daily schedule which is universally used for cyclosporin in the transplant population. The comparatively higher doses and more frequent administration schedule used in paediatric transplant recipients are the consequence of age-related differences in bioavailability and the possibility of increased metabolic clearance of the drug in younger patients.